An observational study in Inflammatory Bowel Diseases, Crohn's Disease and Ulcerative Colitis, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by McMaster University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 156 studies in Inflammatory Bowel Diseases with a site in Canada — 35 open to participants now, 50 under way, 6 of them phase 3. Inflammatory Bowel Diseases · Canada.
Among the 156 studies in Inflammatory Bowel Diseases with a site in Canada, this one is the 36th largest by planned enrollment of the 36 observational ones that give a count, is one of 13 that started in 2024, is one of 36 observational ones, reaches primary completion later than 19 of the 49 other live ones, and was the 134th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →35 of the 156 studies in Inflammatory Bowel Diseases with a site in Canada are open now. Recruiting first, the newest first:
Palisade Bio · Sites in Canada, United States, Czechia and 9 more countries
Ages 18–75
Eli Lilly and Company · Sites in Canada, United States, Denmark and 4 more countries
Ages 3 wk+ · Women only
University of British Columbia · Sites in Canada
Ages 9–17
University of British Columbia · Sites in Canada
Ages 19+ · Women only · Healthy volunteers
University of Alberta · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
156 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 33 · Phase 3 28 · Phase 4 10
First in 2002; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.
Median enrollment 120 across the 119 interventional studies, 157 across the 36 observational. Of the 91 that completed or were terminated, 32 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 156 have an industry lead sponsor. The 10 most frequent:
McMaster University is the lead sponsor of 742 studies on the registry; 127 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
McMaster University has 9 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
14 of the studies in Inflammatory Bowel Diseases with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07434310Phase 3Dr. Naveed SiddiquiUse of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults | 2027-07-01 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07814274University of British ColumbiaProspective Intestinal Ultrasound Study for Artificial Intelligence Algorithm Development | 2027-02-01 |
| NCT05722236Jennifer JonesIBD Strong Peer2Peer for Self-Management of Psychological Distress | 2027-03 |
| NCT06548399McMaster UniversityLongitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease | 2027-03-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 156 studies in Inflammatory Bowel Diseases with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate whether the gut bacteria in IBD patients cause ongoing abdominal pain, even when the disease is calm. Many inflammatory bowel disease (IBD) patients have this pain, regardless of whether their disease is active or not. This might be linked to an imbalance in gut bacteria. Certain IBD patients with persistent abdominal pain experience increased sensitivity in their gut due to bacteria producing LPC and LPA. Our goal is to explore the connection between bacterial LPC/LPA levels and symptoms in IBD patients with long-lasting abdominal pain. Additionally, we aim to pinpoint the specific bacteria responsible for producing LPC/LPA, which in turn causes chronic abdominal pain in these patients.
The human body is inhabited by a complex community of microbes, collectively referred to as "microbiota". A vast majority of these bacteria are found in the lumen of the gastrontestinal tract (colon, small intestine, stomach and esophagus). Several lines of evidence indicate that changes in microbiota (bacteria) may be involved in the origin of different gastrointestinal diseases, including inflammatory Bowel Disease (IBD), with its two main types: Crohn´s disease and Ulcerative colitis.
Recent data suggest that the gut bacteria have the capability to produce lysophosphatidylcholine (LPC) and its derivative, lysophosphatidic acid (LPA), small lipid molecules that were shown previously to be involved in the genesis and maintenance of chronic pain. The investigators found that these molecules are higher in stool of patients with Inflammatory Bowel Disease (IBD), but it is unclear whether 1) they are produced by gut bacteria, and 2) whether their production underlies chronic pain in patients with IBD.
The purpose of this study is to determine whether the gut bacteria produce LPC and LPA and induce chronic abdominal pain, which is common in many patients with IBD, even when their colitis is in remission (absence of overt gut inflammation).
In this exploratory longitudinal study, the investigators will recruit patients with IBD, aged 18-70 years, of both sexes, with a history of moderate to severe chronic abdominal pain (as defined by their gastroenterologist), which persists during remission of colitis (absence of overt inflammation on CT or MRI imaging, and baseline fecal calprotectin less than 200 μg/g of stool) or while having only mild gut inflammation, defined by either colonoscopy (Endoscopic Mayo score: 0-1 or Simple Endoscopic Score for Crohn's Disease score: 0-10). We will recruit 15 patients with baseline stool LPC less that 200 μg/mg and LPA less than 100 μg/mg levels after first assessment in screening visit. Recruitment will take place at McMaster University IBD clinic (https://www.mcmasteribd.com).
After study participant meets the eligibility criteria and signs the informed consent, stool and urine samples will be collected and abdominal pain scores recorded for 3 weeks. Daily stool and urine samples (first stool of the day and morning (overnight) urine) will be collected, and LPC/LPA measured by ELISA. Abdominal pain will be assessed daily with a visual analogue scale (VAS). In addition, clinical symptoms will be evaluated by PROMIS (GI Belly Pain, Diarrhea, Constipation and Bloating) and DASS-21 questionnaires at the end of each week, as they assess symptoms during the preceding 7 days. Dietary intake will be assessed at the beginning of each week by a 3-day food diary. The clinical surveys will be provided online, using RedCap software and secure servers already operational within McMaster.
Patients with a diagnosis of IBD: Crohn\'s disease or Ulcerative colitis followed at McMaster University's Gastroenterology Outpatient Clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Correlation between daily abdominal pain and stool LPC/LPA levels
Time frame: From enrolment to the end of data/sample collection period at 3 weeks
Correlation between daily abdominal pain and urine LPC/LPA levels
Time frame: From enrolment to the end of data/sample collection period at 3 weeks
Correlation between daily abdominal pain and abundance of LPC/LPA producing bacteria in the stool
Time frame: From enrolment to the end of data/sample collection period at 3 weeks
Associations between weekly average stool LPC/LPA levels and overall gastrointestinal symptoms, anxiety, depression and stress.
Time frame: From enrolment to the end of data/sample collection period at 3 weeks
Plan to share: Undecided — It is not yet known if there will be a plan to make IPD available.
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Mar 2027, 27 months after the start.
Of 244 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 132. This study's planned 27 months is below that.
Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.